State Street
MNPR icon

State Street’s Monopar Therapeutics MNPR Stock Holding History

State Street’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.57M Buy
92,551
+4,196
+5% +$260K ﹤0.01% 2766
2026
Q1 		$4.84M Buy
88,355
+4,366
+5% +$264K ﹤0.01% 2978
2025
Q4 		$5.48M Buy
83,989
+11,751
+16% +$960K ﹤0.01% 2955
2025
Q3 		$5.9M Buy
72,238
+30,412
+73% +$1.36M ﹤0.01% 2935
2025
Q2 		$1.5M Buy
41,826
+26,012
+164% +$945K ﹤0.01% 3394
2025
Q1 		$576K Buy
+15,814
New +$570K ﹤0.01% 3561

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street's MNPR Position: Q2 2026 in Review

State Street increased its Monopar Therapeutics (MNPR) stake by 4.7% in Q2 2026, buying an estimated $260K and bringing the position to 92,551 shares worth $8.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2766.

State Street first reported a position in MNPR in Q1 2025 and has held it in 6 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • State Street held 92,551 shares of Monopar Therapeutics worth $8.57M as of Q2 2026.
  • State Street bought 4,196 Monopar Therapeutics shares in Q2 2026, an estimated $260K.
  • Monopar Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2766 holding.
  • State Street first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.